TriSalus Life Sciences (TLSI) Set to Announce Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) will be announcing its earnings results before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The firm had revenue of $7.36 million during the quarter. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Trading Up 0.5 %

NASDAQ:TLSI traded up $0.02 during midday trading on Thursday, hitting $4.18. 15,310 shares of the company traded hands, compared to its average volume of 38,339. The firm has a market capitalization of $122.52 million, a P/E ratio of -1.67 and a beta of 0.49. The firm's fifty day moving average is $4.46 and its 200-day moving average is $6.05. TriSalus Life Sciences has a 12-month low of $3.32 and a 12-month high of $10.42.

Insider Buying and Selling at TriSalus Life Sciences

In related news, CEO Mary T. Szela bought 7,520 shares of the stock in a transaction on Thursday, September 12th. The stock was bought at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the acquisition, the chief executive officer now directly owns 377,382 shares in the company, valued at approximately $1,962,386.40. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 32.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TLSI. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an "outperform" rating and a $12.50 target price on the stock. Northland Capmk raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research report on Friday, October 25th. Finally, Oppenheimer started coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They set an "outperform" rating and a $10.00 target price for the company. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $12.50.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.